Korea Investment Corp’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$654M Buy
711,353
+9,946
+1% +$10.1M 1.36% 11
2025
Q4
$754M Buy
701,407
+25,011
+4% +$23.9M 1.48% 11
2025
Q3
$516M Buy
676,396
+33,060
+5% +$24.6M 1.06% 12
2025
Q2
$501M Sell
643,336
-4,422
-0.7% -$3.44M 1.12% 12
2025
Q1
$535M Sell
647,758
-5,775
-0.9% -$4.81M 1.3% 12
2024
Q4
$505M Sell
653,533
-29,872
-4% -$24.7M 1.2% 11
2024
Q3
$605M Sell
683,405
-13,218
-2% -$11.9M 1.44% 9
2024
Q2
$631M Buy
696,623
+2,095
+0.3% +$1.68M 1.59% 8
2024
Q1
$540M Sell
694,528
-23,922
-3% -$17M 1.37% 8
2023
Q4
$419M Sell
718,450
-65,244
-8% -$38.1M 1.1% 11
2023
Q3
$421M Sell
783,694
-30,519
-4% -$15.7M 1.24% 10
2023
Q2
$382M Sell
814,213
-60,969
-7% -$25.6M 1.07% 12
2023
Q1
$301M Sell
875,182
-17,444
-2% -$5.88M 0.88% 17
2022
Q4
$327M Buy
892,626
+53,536
+6% +$19M 1.03% 13
2022
Q3
$271M Buy
839,090
+42,898
+5% +$13.6M 0.84% 21
2022
Q2
$258M Sell
796,192
-10,864
-1% -$3.26M 0.79% 20
2022
Q1
$231M Buy
807,056
+81,353
+11% +$20.9M 0.57% 27
2021
Q4
$200M Buy
725,703
+216,193
+42% +$54.8M 0.52% 33
2021
Q3
$118M Sell
509,510
-116,154
-19% -$28.7M 0.35% 65
2021
Q2
$144M Buy
625,664
+140,270
+29% +$28.2M 0.41% 51
2021
Q1
$90.7M Sell
485,394
-120,086
-20% -$23.5M 0.29% 102
2020
Q4
$102M Sell
605,480
-29,405
-5% -$4.39M 0.31% 84
2020
Q3
$94M Sell
634,885
-29,300
-4% -$4.53M 0.33% 72
2020
Q2
$109M Buy
664,185
+5,500
+0.8% +$844K 0.4% 56
2020
Q1
$91.4M Sell
658,685
-154,300
-19% -$21.2M 0.4% 54
2019
Q4
$107M Buy
812,985
+44,700
+6% +$5.18M 0.39% 52
2019
Q3
$85.9M Sell
768,285
-21,300
-3% -$2.37M 0.36% 60
2019
Q2
$87.5M Buy
789,585
+7,900
+1% +$930K 0.38% 57
2019
Q1
$101M Sell
781,685
-20,872
-3% -$2.54M 0.46% 46
2018
Q4
$92.9M Sell
802,557
-34,000
-4% -$3.8M 0.5% 44
2018
Q3
$89.8M Buy
836,557
+23,060
+3% +$2.31M 0.41% 57
2018
Q2
$69.4M Buy
813,497
+24,200
+3% +$1.99M 0.32% 76
2018
Q1
$61.1M Sell
789,297
-176,771
-18% -$14.2M 0.28% 89
2017
Q4
$81.6M Buy
966,068
+53,927
+6% +$4.59M 0.37% 66
2017
Q3
$78M Sell
912,141
-12,800
-1% -$1.05M 0.36% 58
2017
Q2
$76.1M Buy
924,941
+23,051
+3% +$1.88M 0.35% 59
2017
Q1
$75.9M Buy
901,890
+219,539
+32% +$17.6M 0.38% 53
2016
Q4
$50.2M Buy
682,351
+16,372
+2% +$1.22M 0.24% 112
2016
Q3
$53.5M Buy
665,979
+99,733
+18% +$7.98M 0.28% 96
2016
Q2
$44.6M Buy
566,246
+77,100
+16% +$5.8M 0.27% 99
2016
Q1
$35.2M Sell
489,146
-27,300
-5% -$2.07M 0.26% 100
2015
Q4
$43.5M Buy
516,446
+47,300
+10% +$3.93M 0.3% 80
2015
Q3
$39.3M Buy
469,146
+117,746
+34% +$9.94M 0.31% 70
2015
Q2
$29.3M Sell
351,400
-44,500
-11% -$3.39M 0.25% 89
2015
Q1
$28.8M Buy
395,900
+63,000
+19% +$4.49M 0.22% 109
2014
Q4
$23M Sell
332,900
-75,400
-18% -$5.09M 0.19% 133
2014
Q3
$26.5M Sell
408,300
-153,300
-27% -$9.71M 0.22% 112
2014
Q2
$34.9M Sell
561,600
-79,400
-12% -$4.74M 0.29% 83
2014
Q1
$37.7M Buy
641,000
+93,700
+17% +$5.23M 0.33% 62
2013
Q4
$27.9M Sell
547,300
-69,700
-11% -$3.49M 0.26% 87
2013
Q3
$31.1M Buy
617,000
+85,600
+16% +$4.48M 0.33% 73
2013
Q2
$26.1M Buy
+531,400
New +$28.9M 0.31% 70

Other funds holding LLY

Korea Investment Corp's LLY Position: Q1 2026 in Review

Korea Investment Corp increased its Eli Lilly (LLY) stake by 1.4% in Q1 2026, buying an estimated $10.1M and bringing the position to 711,353 shares worth $654M. The position accounts for 1.36% of the portfolio, ranked #11.

Korea Investment Corp first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $754M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Korea Investment Corp held 711,353 shares of Eli Lilly worth $654M as of Q1 2026.
  • Korea Investment Corp bought 9,946 Eli Lilly shares in Q1 2026, an estimated $10.1M.
  • Eli Lilly made up 1.36% of Korea Investment Corp's portfolio in Q1 2026, its #11 holding.
  • Korea Investment Corp first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Korea Investment Corp's Eli Lilly position peaked at $754M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Korea Investment Corp's 13F filing for Q1 2026, filed 13 May 2026.